HMGB1 in vascular diseases: Its role in vascular inflammation and atherosclerosis

Autoimmunity Reviews

Volumn 11, Issue 12, 2012, Pages 909-917

  de Souza, A W S ^a,c   Westra, J ^a   Limburg, P C ^a   Bijl, M ^b   Kallenberg, C G M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b MARTINI HOSPITAL   (Netherlands)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Atherosclerosis; HMGB1; RAGE; TLRs; Vasculitis

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBODY; ATORVASTATIN; CELL ADHESION MOLECULE; CYTOKINE; HIGH MOBILITY GROUP B1 PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN ANTIBODY; IMMUNOGLOBULIN; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ANCA ASSOCIATED VASCULITIS; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; ATHEROSCLEROTIC PLAQUE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CELL NUCLEUS; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY ANEURYSM; CORONARY ARTERY DISEASE; CYTOPLASM; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL MODEL; HUMAN; ISCHEMIC HEART DISEASE; MACROPHAGE; MORTALITY; MUCOCUTANEOUS LYMPH NODE SYNDROME; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; NONHUMAN; PATHOGENESIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REVIEW; SMOOTH MUSCLE FIBER; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STROKE; TISSUE LEVEL; VASCULAR DISEASE; VASCULITIS; WESTERN BLOTTING;

ANIMALS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HMGB1 PROTEIN; HUMANS; MODELS, ANIMAL; VASCULITIS;

EID: 84866528161     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2012.03.007     Document Type: Review

References (104)

1. Read C.M., Cary P.D., Crane-Robinson C., Driscoll P.C., Norman D.G. Solution structure of a DNA-binding domain from HMG1. Nucleic Acids Res 1993, 21:3427-3436.
2. Tsuda K., Kikuchi M., Mori K., Waga S., Yoshida M. Primary structure of non-histone protein HMG1 revealed by the nucleotide sequence. Biochemistry 1988, 27:6159-6163.
3. Einck L., Bustin M. The intracellular distribution and function of the high mobility group chromosomal proteins. Exp Cell Res 1985, 156:295-310.
4. Abdulahad D.A., Westra J., Limburg P.C., Kallenberg C.G., Bijl M. HMGB1 in systemic lupus erythematosus: its role in cutaneous lesions development. Autoimmun Rev 2010, 9:661-665.
5. Wang H., Bloom O., Zhang M., Vishnubhakat J.M., Ombrellino M., Che J., et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999, 285:248-251.
6. Rendon-Mitchell B., Ochani M., Li J., Han J., Wang H., Yang H., et al. IFN-gamma induces high mobility group box 1 protein release partly through a TNF-dependent mechanism. J Immunol 2003, 170:3890-3897.
7. Kazama H., Ricci J.E., Herndon J.M., Hoppe G., Green D.R., Ferguson T.A. Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity 2008, 29:21-32.
8. Yu M., Wang H., Ding A., Golenbock D.T., Latz E., Czura C.J., et al. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 2006, 26:174-179.
9. Park J.S., Svetkauskaite D., He Q., Kim J.Y., Strassheim D., Ishizaka A., et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004, 279:7370-7377.
10. Tian J., Avalos A.M., Mao S.Y., Chen B., Senthil K., Wu H., et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007, 8:487-496.
11. Andersson U., Tracey K.J. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol 2011, 29:139-162.
12. Gao H.M., Zhou H., Zhang F., Wilson B.C., Kam W., Hong J.S. HMGB1 acts on microglia Mac1 to mediate chronic neuroinflammation that drives progressive neurodegeneration. J Neurosci 2011, 31:1081-1092.
13. El Mezayen R., El Gazzar M., Seeds M.C., McCall C.E., Dreskin S.C., Nicolls M.R. Endogenous signals released from necrotic cells augment inflammatory responses to bacterial endotoxin. Immunol Lett 2007, 111:36-44.
14. Salmivirta M., Rauvala H., Elenius K., Jalkanen M. Neurite growth-promoting protein (amphoterin, p30) binds syndecan. Exp Cell Res 1992, 200:444-451.
15. Campana L., Bosurgi L., Bianchi M.E., Manfredi A.A., Rovere-Querini P. Requirement of HMGB1 for stromal cell-derived factor-1/CXCL12-dependent migration of macrophages and dendritic cells. J Leukoc Biol 2009, 86:609-615.
16. Yanai H., Ban T., Wang Z., Choi M.K., Kawamura T., Negishi H., et al. HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses. Nature 2009, 462:99-103.
17. Yang H., Hreggvidsdottir H.S., Palmblad K., Wang H., Ochani M., Li J., et al. A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci U S A 2010, 107:11942-11947.
18. Rouhiainen A., Kuja-Panula J., Wilkman E., Pakkanen J., Stenfors J., Tuominen R.K., et al. Regulation of monocyte migration by amphoterin (HMGB1). Blood 2004, 104:1174-1182.
19. Messmer D., Yang H., Telusma G., Knoll F., Li J., Messmer B., et al. High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J Immunol 2004, 173:307-313.
20. Yang D., Chen Q., Yang H., Tracey K.J., Bustin M., Oppenheim J.J. High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J Leukoc Biol 2007, 81:59-66.
21. Fan J., Li Y., Levy R.M., Fan J.J., Hackam D.J., Vodovotz Y., et al. Hemorrhagic shock induces NAD(P)H oxidase activation in neutrophils: role of HMGB1-TLR4 signaling. J Immunol 2007, 178:6573-6580.
22. Berthelot F., Fattoum L., Casulli S., Gozlan J., Marechal V., Elbim C. The effect of HMGB1, a damage-associated molecular pattern molecule, on polymorphonuclear neutrophil migration depends on its concentration. J Innate Immun 2012, 4:41-58.
23. Silva E., Arcaroli J., He Q., Svetkauskaite D., Coldren C., Nick J.A., et al. HMGB1 and LPS induce distinct patterns of gene expression and activation in neutrophils from patients with sepsis-induced acute lung injury. Intensive Care Med 2007, 33:1829-1839.
24. Orlova V.V., Choi E.Y., Xie C., Chavakis E., Bierhaus A., Ihanus E., et al. A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J 2007, 26:1129-1139.
25. Sundberg E., Fasth A.E., Palmblad K., Harris H.E., Andersson U. High mobility group box chromosomal protein 1 acts as a proliferation signal for activated T lymphocytes. Immunobiology 2009, 214:303-309.
26. Huang L.F., Yao Y.M., Meng H.D., Zhao X.D., Dong N., Yu Y., et al. The effect of high mobility group box-1 protein on immune function of human T lymphocytes in vitro. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2008, 20:7-13.
27. Liu Q.Y., Yao Y.M., Yan Y.H., Dong N., Sheng Z.Y. High mobility group box 1 protein suppresses T cell-mediated immunity via CD11c(low)CD45RB(high) dendritic cell differentiation. Cytokine 2011, 54:205-211.
28. Shi Y., Sandoghchian Shotorbani S., Su Z., Liu Y., Tong J., Zheng D., et al. Enhanced HMGB1 expression may contribute to Th17 cells activation in rheumatoid arthritis. Clin Dev Immunol 2012, 2012:295081.
29. Zhu X.M., Yao Y.M., Liang H.P., Xu C.T., Dong N., Yu Y., et al. High mobility group box-1 protein regulate immunosuppression of regulatory T cells through toll-like receptor 4. Cytokine 2011, 54:296-304.
30. Zhang Y., Yao Y.M., Huang L.F., Dong N., Yu Y., Sheng Z.Y. The potential effect and mechanism of high-mobility group box 1 protein on regulatory T cell-mediated immunosuppression. J Interferon Cytokine Res 2011, 31:249-257.
31. Avalos A.M., Kiefer K., Tian J., Christensen S., Shlomchik M., Coyle A.J., et al. RAGE-independent autoreactive B cell activation in response to chromatin and HMGB1/DNA immune complexes. Autoimmunity 2010, 43:103-110.
32. Vettermann C., Castor D., Mekker A., Gerrits B., Karas M., Jack H.M. Proteome profiling suggests a pro-inflammatory role for plasma cells through release of high-mobility group box 1 protein. Proteomics 2011, 11:1228-1237.
33. Abdulahad D.A., Westra J., Bijzet J., Limburg P.C., Kallenberg C.G., Bijl M. High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus. Arthritis Res Ther 2011, 13:R71.
34. Yamada S., Yakabe K., Ishii J., Imaizumi H., Maruyama I. New high mobility group box 1 assay system. Clin Chim Acta 2006, 372:173-178.
35. Ilmakunnas M., Tukiainen E.M., Rouhiainen A., Rauvala H., Arola J., Nordin A., et al. High mobility group box 1 protein as a marker of hepatocellular injury in human liver transplantation. Liver Transpl 2008, 14:1517-1525.
36. Muller S., Scaffidi P., Degryse B., Bonaldi T., Ronfani L., Agresti A., et al. New EMBO members' review: the double life of HMGB1 chromatin protein: architectural factor and extracellular signal. EMBO J 2001, 20:4337-4340.
37. Abeyama K., Stern D.M., Ito Y., Kawahara K., Yoshimoto Y., Tanaka M., et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest 2005, 115:1267-1274.
38. Urbonaviciute V., Furnrohr B.G., Weber C., Haslbeck M., Wilhelm S., Herrmann M., et al. Factors masking HMGB1 in human serum and plasma. J Leukoc Biol 2007, 81:67-74.
39. af Klint E., Grundtman C., Engstrom M., Catrina A.I., Makrygiannakis D., Klareskog L., et al. Intraarticular glucocorticoid treatment reduces inflammation in synovial cell infiltrations more efficiently than in synovial blood vessels. Arthritis Rheum 2005, 52:3880-3889.
40. Barkauskaite V., Ek M., Popovic K., Harris H.E., Wahren-Herlenius M., Nyberg F. Translocation of the novel cytokine HMGB1 to the cytoplasm and extracellular space coincides with the peak of clinical activity in experimentally UV-induced lesions of cutaneous lupus erythematosus. Lupus 2007, 16:794-802.
41. Kostova N., Zlateva S., Ugrinova I., Pasheva E. The expression of HMGB1 protein and its receptor RAGE in human malignant tumors. Mol Cell Biochem 2010, 337:251-258.
42. Ek M., Popovic K., Harris H.E., Naucler C.S., Wahren-Herlenius M. Increased extracellular levels of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in minor salivary glands of patients with Sjogren's syndrome. Arthritis Rheum 2006, 54:2289-2294.
43. Ulfgren A.K., Grundtman C., Borg K., Alexanderson H., Andersson U., Harris H.E., et al. Down-regulation of the aberrant expression of the inflammation mediator high mobility group box chromosomal protein 1 in muscle tissue of patients with polymyositis and dermatomyositis treated with corticosteroids. Arthritis Rheum 2004, 50:1586-1594.
44. Hoshina T., Kusuhara K., Ikeda K., Mizuno Y., Saito M., Hara T. High mobility group box 1 (HMGB1) and macrophage migration inhibitory factor (MIF) in Kawasaki disease. Scand J Rheumatol 2008, 37:445-449.
45. Eguchi T., Nomura Y., Hashiguchi T., Masuda K., Arata M., Hazeki D., et al. An elevated value of high mobility group box 1 is a potential marker for poor response to high-dose of intravenous immunoglobulin treatment in patients with Kawasaki syndrome. Pediatr Infect Dis J 2009, 28:339-341.
46. Henes F., Chen Y., Bley T., Fabel M., Both M., Herrmann K., et al. Correlation of serum level of high mobility group box 1 with the burden of granulomatous inflammation in granulomatosis with polyangiitis (Wegener's). Ann Rheum Dis 2011, 70:1926-1929.
47. Bruchfeld A., Wendt M., Bratt J., Qureshi A.R., Chavan S., Tracey K.J., et al. High-mobility group box-1 protein (HMGB1) is increased in antineutrophilic cytoplasmatic antibody (ANCA)-associated vasculitis with renal manifestations. Mol Med 2011, 17:29-35.
48. Sato F., Maruyama S., Hayashi H., Sakamoto I., Yamada S., Uchimura T., et al. High mobility group box chromosomal protein 1 in patients with renal diseases. Nephron Clin Pract 2008, 108:c194-c201.
49. Wibisono D., Csernok E., Lamprecht P., Holle J.U., Gross W.L., Moosig F. Serum HMGB1 levels are increased in active Wegener's granulomatosis and differentiate between active forms of ANCA-associated vasculitis. Ann Rheum Dis 2010, 69:1888-1889.
50. Barnay-Verdier S., Fattoum L., Borde C., Kaveri S., Gibot S., Marechal V. Emergence of autoantibodies to HMGB1 is associated with survival in patients with septic shock. Intensive Care Med 2011, 37:957-962.
51. Oates-Whitehead R.M., Baumer J.H., Haines L., Love S., Maconochie I.K., Gupta A., et al. Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev 2003, CD004000.
52. Kobayashi T., Inoue Y., Takeuchi K., Okada Y., Tamura K., Tomomasa T., et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 2006, 113:2606-2612.
53. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999, 340:115-126.
54. Libby P., Ridker P.M., Hansson G.K. Progress and challenges in translating the biology of atherosclerosis. Nature 2011, 473:317-325.
55. Rautou P.E., Vion A.C., Amabile N., Chironi G., Simon A., Tedgui A., et al. Microparticles, vascular function, and atherothrombosis. Circ Res 2011, 109:593-606.
56. Badimon L., Storey R.F., Vilahur G. Update on lipids, inflammation and atherothrombosis. Thromb Haemost 2011, 105(Suppl. 1):S34-S42.
57. Kalinina N., Agrotis A., Antropova Y., DiVitto G., Kanellakis P., Kostolias G., et al. Increased expression of the DNA-binding cytokine HMGB1 in human atherosclerotic lesions: role of activated macrophages and cytokines. Arterioscler Thromb Vasc Biol 2004, 24:2320-2325.
58. Inoue K., Kawahara K., Biswas K.K., Ando K., Mitsudo K., Nobuyoshi M., et al. HMGB1 expression by activated vascular smooth muscle cells in advanced human atherosclerosis plaques. Cardiovasc Pathol 2007, 16:136-143.
59. Porto A., Palumbo R., Pieroni M., Aprigliano G., Chiesa R., Sanvito F., et al. Smooth muscle cells in human atherosclerotic plaques secrete and proliferate in response to high mobility group box 1 protein. FASEB J 2006, 20:2565-2566.
60. Rouhiainen A., Imai S., Rauvala H., Parkkinen J. Occurrence of amphoterin (HMG1) as an endogenous protein of human platelets that is exported to the cell surface upon platelet activation. Thromb Haemost 2000, 84:1087-1094.
61. Fiuza C., Bustin M., Talwar S., Tropea M., Gerstenberger E., Shelhamer J.H., et al. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 2003, 101:2652-2660.
62. Treutiger C.J., Mullins G.E., Johansson A.S., Rouhiainen A., Rauvala H.M., Erlandsson-Harris H., et al. High mobility group 1 B-box mediates activation of human endothelium. J Intern Med 2003, 254:375-385.
63. Kanellakis P., Agrotis A., Kyaw T.S., Koulis C., Ahrens I., Mori S., et al. High-mobility group box protein 1 neutralization reduces development of diet-induced atherosclerosis in apolipoprotein e-deficient mice. Arterioscler Thromb Vasc Biol 2011, 31:313-319.
64. Yang J., Huang C., Yang J., Jiang H., Ding J. Statins attenuate high mobility group box-1 protein induced vascular endothelial activation: a key role for TLR4/NF-kappaB signaling pathway. Mol Cell Biochem 2010, 345:189-195.
65. Haraba R., Suica V.I., Uyy E., Ivan L., Antohe F. Hyperlipidemia stimulates the extracellular release of the nuclear high mobility group box 1 protein. Cell Tissue Res 2011, 346:361-368.
66. Biscetti F., Straface G., De Cristofaro R., Lancellotti S., Rizzo P., Arena V., et al. High-mobility group box-1 protein promotes angiogenesis after peripheral ischemia in diabetic mice through a VEGF-dependent mechanism. Diabetes 2010, 59:1496-1505.
67. Xu H., Yao Y., Su Z., Yang Y., Kao R., Martin C.M., et al. Endogenous HMGB1 contributes to ischemia-reperfusion-induced myocardial apoptosis by potentiating the effect of TNF-α/JNK. Am J Physiol Heart Circ Physiol 2011, 300:H913-H921.
68. Andrassy M., Volz H.C., Igwe J.C., Funke B., Eichberger S.N., Kaya Z., et al. High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation 2008, 117:3216-3226.
69. Kitahara T., Takeishi Y., Harada M., Niizeki T., Suzuki S., Sasaki T., et al. High-mobility group box 1 restores cardiac function after myocardial infarction in transgenic mice. Cardiovasc Res 2008, 80:40-46.
70. Limana F., Germani A., Zacheo A., Kajstura J., Di Carlo A., Borsellino G., et al. Exogenous high-mobility group box 1 protein induces myocardial regeneration after infarction via enhanced cardiac C-kit+ cell proliferation and differentiation. Circ Res 2005, 97:e73-e83.
71. Takahashi K., Fukushima S., Yamahara K., Yashiro K., Shintani Y., Coppen S.R., et al. Modulated inflammation by injection of high-mobility group box 1 recovers post-infarction chronically failing heart. Circulation 2008, 118:S106-S114.
72. Limana F., Esposito G., D'Arcangelo D., Di Carlo A., Romani S., Melillo G., et al. HMGB1 attenuates cardiac remodelling in the failing heart via enhanced cardiac regeneration and miR-206-mediated inhibition of TIMP-3. PLoS One 2011, 6:e19845.
73. Rossini A., Zacheo A., Mocini D., Totta P., Facchiano A., Castoldi R., et al. HMGB1-stimulated human primary cardiac fibroblasts exert a paracrine action on human and murine cardiac stem cells. J Mol Cell Cardiol 2008, 44:683-693.
74. Schlueter C., Weber H., Meyer B., Rogalla P., Roser K., Hauke S., et al. Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule. Am J Pathol 2005, 166:1259-1263.
75. Mitola S., Belleri M., Urbinati C., Coltrini D., Sparatore B., Pedrazzi M., et al. Cutting edge: extracellular high mobility group box-1 protein is a proangiogenic cytokine. J Immunol 2006, 176:12-15.
76. Chavakis E., Hain A., Vinci M., Carmona G., Bianchi M.E., Vajkoczy P., et al. High-mobility group box 1 activates integrin-dependent homing of endothelial progenitor cells. Circ Res 2007, 100:204-212.
77. Abarbanell A.M., Hartley J.A., Herrmann J.L., Weil B.R., Wang Y., Manukyan M.C., et al. Exogenous high-mobility group box 1 improves myocardial recovery after acute global ischemia/reperfusion injury. Surgery 2011, 149:329-335.
78. Takahashi M. High-mobility group box 1 protein (HMGB1) in ischaemic heart disease: beneficial or deleterious?. Cardiovasc Res 2008, 80:5-6.
79. Goldstein R.S., Gallowitsch-Puerta M., Yang L., Rosas-Ballina M., Huston J.M., Czura C.J., et al. Elevated high-mobility group box 1 levels in patients with cerebral and myocardial ischemia. Shock 2006, 25:571-574.
80. Yan X.X., Lu L., Peng W.H., Wang L.J., Zhang Q., Zhang R.Y., et al. Increased serum HMGB1 level is associated with coronary artery disease in nondiabetic and type 2 diabetic patients. Atherosclerosis 2009, 205:544-548.
81. Andrassy M., Volz H.C., Riedle N., Gitsioudis G., Seidel C., Laohachewin D., et al. HMGB1 as a predictor of infarct transmurality and functional recovery in patients with myocardial infarction. J Intern Med 2011, 270:245-253.
82. Sorensen M.V., Pedersen S., Mogelvang R., Skov-Jensen J., Flyvbjerg A. Plasma high-mobility group box 1 levels predict mortality after ST-segment elevation myocardial infarction. JACC Cardiovasc Interv 2011, 4:281-286.
83. Cirillo P., Giallauria F., Pacileo M., Petrillo G., D'Agostino M., Vigorito C., et al. Increased high mobility group box-1 protein levels are associated with impaired cardiopulmonary and echocardiographic findings after acute myocardial infarction. J Card Fail 2009, 15:362-367.
84. Giallauria F., Cirillo P., D'agostino M., Petrillo G., Vitelli A., Pacileo M., et al. Effects of exercise training on high-mobility group box-1 levels after acute myocardial infarction. J Card Fail 2011, 17:108-114.
85. Hayakawa K., Qiu J., Lo E.H. Biphasic actions of HMGB1 signaling in inflammation and recovery after stroke. Ann N Y Acad Sci 2010, 1207:50-57.
86. Lakhan S.E., Kirchgessner A., Hofer M. Inflammatory mechanisms in ischemic stroke: therapeutic approaches. J Transl Med 2009, 7:97.
87. Kim J.B., Lim C.M., Yu Y.M., Lee J.K. Induction and subcellular localization of high-mobility group box-1 (HMGB1) in the postischemic rat brain. J Neurosci Res 2008, 86:1125-1131.
88. Faraco G., Fossati S., Bianchi M.E., Patrone M., Pedrazzi M., Sparatore B., et al. High mobility group box 1 protein is released by neural cells upon different stresses and worsens ischemic neurodegeneration in vitro and in vivo. J Neurochem 2007, 103:590-603.
89. Kim J.B., Sig Choi J., Yu Y.M., Nam K., Piao C.S., Kim S.W., et al. HMGB1, a novel cytokine-like mediator linking acute neuronal death and delayed neuroinflammation in the postischemic brain. J Neurosci 2006, 26:6413-6421.
90. Qiu J., Nishimura M., Wang Y., Sims J.R., Qiu S., Savitz S.I., et al. Early release of HMGB-1 from neurons after the onset of brain ischemia. J Cereb Blood Flow Metab 2008, 28:927-938.
91. Muhammad S., Barakat W., Stoyanov S., Murikinati S., Yang H., Tracey K.J., et al. The HMGB1 receptor RAGE mediates ischemic brain damage. J Neurosci 2008, 28:12023-12031.
92. Qiu J., Xu J., Zheng Y., Wei Y., Zhu X., Lo E.H., et al. High-mobility group box 1 promotes metalloproteinase-9 upregulation through Toll-like receptor 4 after cerebral ischemia. Stroke 2010, 41:2077-2082.
93. Liu K., Mori S., Takahashi H.K., Tomono Y., Wake H., Kanke T., et al. Anti-high mobility group box 1 monoclonal antibody ameliorates brain infarction induced by transient ischemia in rats. FASEB J 2007, 21:3904-3916.
94. Zhang J., Takahashi H.K., Liu K., Wake H., Liu R., Maruo T., et al. Anti-high mobility group box-1 monoclonal antibody protects the blood-brain barrier from ischemia-induced disruption in rats. Stroke 2011, 42:1420-1428.
95. Hayakawa K., Mishima K., Irie K., Hazekawa M., Mishima S., Fujioka M., et al. Cannabidiol prevents a post-ischemic injury progressively induced by cerebral ischemia via a high-mobility group box1-inhibiting mechanism. Neuropharmacology 2008, 55:1280-1286.
96. Hayakawa K., Mishima K., Nozako M., Hazekawa M., Mishima S., Fujioka M., et al. Delayed treatment with minocycline ameliorates neurologic impairment through activated microglia expressing a high-mobility group box1-inhibiting mechanism. Stroke 2008, 39:951-958.
97. Kikuchi K., Kawahara K., Tancharoen S., Matsuda F., Morimoto Y., Ito T., et al. The free radical scavenger edaravone rescues rats from cerebral infarction by attenuating the release of high-mobility group box-1 in neuronal cells. J Pharmacol Exp Ther 2009, 329:865-874.
98. Wang L., Zhang X., Liu L., Yang R., Cui L., Li M. Atorvastatin protects rat brains against permanent focal ischemia and downregulates HMGB1, HMGB1 receptors (RAGE and TLR4), NF-kappaB expression. Neurosci Lett 2010, 471:152-156.
99. Ye X., Chopp M., Liu X., Zacharek A., Cui X., Yan T., et al. Niaspan reduces high-mobility group box 1/receptor for advanced glycation endproducts after stroke in type-1 diabetic rats. Neuroscience 2011, 190:339-345.
100. Jiang W.L., Xu Y., Zhang S.P., Zhu H.B., Hou J. Tricin 7-glucoside protects against experimental cerebral ischemia by reduction of NF-kappaB and HMGB1 expression. Eur J Pharm Sci 2012, 45:50-57.
101. Hayakawa K., Nakano T., Irie K., Higuchi S., Fujioka M., Orito K., et al. Inhibition of reactive astrocytes with fluorocitrate retards neurovascular remodeling and recovery after focal cerebral ischemia in mice. J Cereb Blood Flow Metab 2010, 30:871-882.
102. Huttunen H.J., Kuja-Panula J., Sorci G., Agneletti A.L., Donato R., Rauvala H. Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation. J Biol Chem 2000, 275:40096-40105.
103. Vogelgesang A., May V.E., Grunwald U., Bakkeboe M., Langner S., Wallaschofski H., et al. Functional status of peripheral blood T-cells in ischemic stroke patients. PLoS One 2010, 5:e8718.
104. Zhou Y., Xiong K.L., Lin S., Zhong Q., Lu F.L., Liang H., et al. Elevation of high-mobility group protein box-1 in serum correlates with severity of acute intracerebral hemorrhage. Mediators Inflamm 2010, (2010):142458. Epub 2010 Sep 29.